SCHEMBL18010076

SCHEMBL18010076

O=C(Nc1ccc(S(F)(F)(F)(F)F)cc1)c1ncccc1O

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
PDGFRB P09619 1/20 0.50
KIT P10721 1/20 0.50
PDGFRA P16234 1/20 0.50
FLT3 P36888 1/20 0.50
KDM4E B2RXH2 1/20 0.49
EGLN2 Q96KS0 1/20 0.48
FTO Q9C0B1 1/20 0.48
GRM4 Q14833 7/20 0.47
TLR7 Q9NYK1 5/20 0.46
PRKCI P41743 1/20 0.44
PIM1 P11309 1/20 0.44
ATR Q13535 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13201028 0.82 ATR (0.61) CSF1RRETPDGFRBKITPDGFRA
SCHEMBL18027788 0.81 KDM4E (0.73) CSF1RRETPDGFRBKITPDGFRA
SCHEMBL18993449 0.81 CSF1R (0.53) CSF1RRETPDGFRBKITPDGFRA
SCHEMBL14284354 0.81 TLR7 (0.67) CSF1RRETPDGFRBKITPDGFRA
SCHEMBL18010086 0.80 TRPV1 (0.44) KDM4EGRM4PRKCI
SCHEMBL18010199 0.80 KDM4E (0.49) KDM4EGRM4PRKCI
SCHEMBL18010172 0.78 GRM4 (0.60) KDM4EGRM4
SCHEMBL5583624 0.76 EGLN2 (0.54) CSF1RRETPDGFRBKITPDGFRA
SCHEMBL5583780 0.76 PNLIP (0.63)
SCHEMBL14284358 0.74 TLR7 (0.62) TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682931-B2 Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof UBE INDUSTRIES, LTD. (JP) 2017-06-20 US disclosed
US-9682931-B2 Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof UBE INDUSTRIES, LTD. (JP) 2017-06-20 US disclosed
EP-3064489-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF Ube Industries, Ltd. (JP) 2016-09-07 EP disclosed
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF UBE INDUSTRIES, LTD. (JP) 2016-08-25 US disclosed
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF UBE INDUSTRIES, LTD. (JP) 2016-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF SLCO1B1, SLCO2B1, SLCO1B3 CSF1R 2776/4885RET 827/4885PDGFRB 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.